Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CM 101 - Chemomab Therapeutics

Next Previous
Drug Profile

CM 101 - Chemomab Therapeutics

Alternative Names: CM-101 - Chemomab Therapeutics

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chemomab Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Chemokine CCL24 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis; Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • Phase I Non-alcoholic fatty liver disease; Systemic scleroderma
  • No development reported Idiopathic pulmonary fibrosis

Most Recent Events

  • 25 Mar 2024 Chemomab Therapeutics has patent protection for the use of CM 101 in the treatment of Hepatic diseases in Europe
  • 02 Feb 2024 Chemomab Therapeutics has patent protection for CM 101 in Israel related to use of CM-101 in the treatment of hepatic (liver) diseases, including primary sclerosing cholangitis
  • 03 Jan 2024 ChemomAb completes enrolment in its phase II SPRING trial for Primary sclerosing cholangitis in United Kingdom, USA, Germany, Israel, Spain (IV, Infusion) (NCT04595825)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top